Frank Mercurio

Chief Scientific Officer
BioTheryX, Inc.
Frank Mercurio has over 25 years of research experience studying the molecular mechanisms underlying cancer and inflammation. Frank was Senior Director of Discovery Biology at Celgene where he initiated and successfully managed numerous Target and Drug Discovery programs. Among his key discoveries, Frank’s team elucidated the mechanistic process regulating activation of the NF-kB signaling pathway, which plays a critical role in the onset and progression of many types of cancer and inflammation. This program resulted in the identification of several novel therapeutic targets within the NF-kB pathway, creating several internal and partnered drug discovery programs. Frank also pioneered the development of an internal E3 Ubiquitin Ligase Program to identify small molecule modulators of protein degradation, an emerging area of drug development with enormous therapeutic potential. Another major focus of Frank's work was to develop technologies that enable the elucidation of drug mechanism of action. While at Celgene, he implemented these technologies to advance the understanding of Thalidomide and Lenalidomide mechanism of action.  


No data was found

Download Brochure

Full details regarding the R&D Series are available for download in the Conference Brochure